Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -51.2 Million USD | -24.73% |
| 2022 | -41.05 Million USD | 37.09% |
| 2021 | -65.26 Million USD | -19.29% |
| 2020 | -54.7 Million USD | -112.9% |
| 2019 | -25.69 Million USD | 10.98% |
| 2018 | -28.86 Million USD | -147.56% |
| 2017 | -11.66 Million USD | 15.86% |
| 2016 | -13.85 Million USD | -31.49% |
| 2015 | -10.53 Million USD | 8.38% |
| 2014 | -11.5 Million USD | -18.28% |
| 2013 | -9.72 Million USD | -80.12% |
| 2012 | -5.39 Million USD | -20.59% |
| 2011 | -4.47 Million USD | 13.18% |
| 2010 | -5.15 Million USD | -202.08% |
| 2009 | 5.05 Million USD | 162.16% |
| 2008 | -8.12 Million USD | -27.6% |
| 2007 | -6.37 Million USD | 29.31% |
| 2006 | -9.01 Million USD | 44.59% |
| 2005 | -16.26 Million USD | 7.49% |
| 2004 | -17.58 Million USD | 20.95% |
| 2003 | -22.24 Million USD | -83.52% |
| 2002 | -12.11 Million USD | -37.32% |
| 2001 | -8.82 Million USD | 10.81% |
| 2000 | -9.89 Million USD | -72.42% |
| 1999 | -5.73 Million USD | -83.96% |
| 1998 | -3.11 Million USD | 3.32% |
| 1997 | -3.22 Million USD | 7.35% |
| 1996 | -3.48 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.64 Million USD | 19.36% |
| 2024 Q2 | -7.25 Million USD | 24.77% |
| 2023 FY | -51.2 Million USD | -24.73% |
| 2023 Q1 | -13.12 Million USD | -36.79% |
| 2023 Q2 | -14.12 Million USD | -7.65% |
| 2023 Q3 | -11.44 Million USD | 18.98% |
| 2023 Q4 | -11.95 Million USD | -4.44% |
| 2022 FY | -41.05 Million USD | 37.09% |
| 2022 Q4 | -9.59 Million USD | -3.41% |
| 2022 Q1 | -11.48 Million USD | 52.8% |
| 2022 Q2 | -10.34 Million USD | 9.86% |
| 2022 Q3 | -9.27 Million USD | 10.34% |
| 2021 Q3 | -11.33 Million USD | 15.86% |
| 2021 Q4 | -24.32 Million USD | -114.63% |
| 2021 Q2 | -13.47 Million USD | 16.99% |
| 2021 Q1 | -16.22 Million USD | -10.29% |
| 2021 FY | -65.26 Million USD | -19.29% |
| 2020 Q1 | -11.52 Million USD | -49.51% |
| 2020 Q2 | -15.75 Million USD | -36.65% |
| 2020 Q4 | -14.71 Million USD | -11.05% |
| 2020 Q3 | -13.24 Million USD | 15.88% |
| 2020 FY | -54.7 Million USD | -112.9% |
| 2019 Q3 | -6.84 Million USD | -10.07% |
| 2019 Q2 | -6.21 Million USD | -12.93% |
| 2019 Q1 | -5.5 Million USD | 12.1% |
| 2019 FY | -25.69 Million USD | 10.98% |
| 2019 Q4 | -7.7 Million USD | -12.64% |
| 2018 Q3 | -5.53 Million USD | 46.1% |
| 2018 FY | -28.86 Million USD | -147.56% |
| 2018 Q1 | -6.81 Million USD | -137.46% |
| 2018 Q2 | -10.26 Million USD | -50.6% |
| 2018 Q4 | -6.26 Million USD | -13.25% |
| 2017 Q3 | -2.66 Million USD | -7.07% |
| 2017 FY | -11.66 Million USD | 15.86% |
| 2017 Q1 | -3.26 Million USD | -11.8% |
| 2017 Q2 | -2.49 Million USD | 23.69% |
| 2017 Q4 | -2.86 Million USD | -7.55% |
| 2016 FY | -13.85 Million USD | -31.49% |
| 2016 Q4 | -2.92 Million USD | 4.4% |
| 2016 Q3 | -3.05 Million USD | 29.56% |
| 2016 Q2 | -4.33 Million USD | -11.01% |
| 2016 Q1 | -3.9 Million USD | -22.37% |
| 2015 FY | -10.53 Million USD | 8.38% |
| 2015 Q1 | -2.81 Million USD | 8.82% |
| 2015 Q4 | -3.19 Million USD | -31.45% |
| 2015 Q3 | -2.42 Million USD | 10.4% |
| 2015 Q2 | -2.71 Million USD | 3.7% |
| 2014 FY | -11.5 Million USD | -18.28% |
| 2014 Q4 | -3.08 Million USD | -82332.75% |
| 2014 Q3 | -3745.32 USD | 99.9% |
| 2014 Q2 | -3.89 Million USD | -77.9% |
| 2014 Q1 | -2.18 Million USD | 17.03% |
| 2013 FY | -9.72 Million USD | -80.12% |
| 2013 Q4 | -2.63 Million USD | -152.34% |
| 2013 Q2 | -1.24 Million USD | 6.74% |
| 2013 Q3 | -1.04 Million USD | 16.38% |
| 2013 Q1 | -1.33 Million USD | 17.53% |
| 2012 FY | -5.39 Million USD | -20.59% |
| 2012 Q1 | -1.02 Million USD | 27.08% |
| 2012 Q2 | -855.62 Thousand USD | 16.84% |
| 2012 Q3 | -1.27 Million USD | -48.64% |
| 2012 Q4 | -1.62 Million USD | -27.67% |
| 2011 Q2 | -1.06 Million USD | 34.03% |
| 2011 Q1 | -1.61 Million USD | -31.32% |
| 2011 Q3 | -1.14 Million USD | -7.29% |
| 2011 Q4 | -1.41 Million USD | -23.33% |
| 2011 FY | -4.47 Million USD | 13.18% |
| 2010 Q3 | -1.09 Million USD | 37.25% |
| 2010 FY | -5.15 Million USD | -202.08% |
| 2010 Q1 | -1.27 Million USD | -6.75% |
| 2010 Q2 | -1.75 Million USD | -37.03% |
| 2010 Q4 | -1.23 Million USD | -12.04% |
| 2009 FY | 5.05 Million USD | 162.16% |
| 2009 Q4 | -1.19 Million USD | -113.43% |
| 2009 Q3 | 8.91 Million USD | 437.26% |
| 2009 Q2 | -2.64 Million USD | -35.86% |
| 2009 Q1 | -1.94 Million USD | -5.75% |
| 2008 Q1 | -3.92 Million USD | -39.14% |
| 2008 Q2 | 2.79 Million USD | 171.16% |
| 2008 FY | -8.12 Million USD | -27.6% |
| 2008 Q3 | -2.08 Million USD | -174.6% |
| 2008 Q4 | -1.83 Million USD | 11.82% |
| 2007 Q1 | -1.76 Million USD | 35.49% |
| 2007 Q4 | -2.82 Million USD | -174.72% |
| 2007 Q3 | 3.77 Million USD | 270.11% |
| 2007 Q2 | -2.22 Million USD | -26.07% |
| 2007 FY | -6.37 Million USD | 29.31% |
| 2006 Q1 | -3.59 Million USD | 17.61% |
| 2006 FY | -9.01 Million USD | 44.59% |
| 2006 Q4 | -2.73 Million USD | -8.97% |
| 2006 Q3 | -2.5 Million USD | 20.09% |
| 2006 Q2 | -3.13 Million USD | 12.86% |
| 2005 Q2 | -3.42 Million USD | 19.82% |
| 2005 Q1 | -4.27 Million USD | 14.63% |
| 2005 Q4 | -4.36 Million USD | 9.65% |
| 2005 Q3 | -4.83 Million USD | -41.06% |
| 2005 FY | -16.26 Million USD | 7.49% |
| 2004 Q2 | -5.5 Million USD | 9.94% |
| 2004 Q4 | -5 Million USD | -5.26% |
| 2004 Q3 | -4.75 Million USD | 13.62% |
| 2004 Q1 | -6.11 Million USD | -32.32% |
| 2004 FY | -17.58 Million USD | 20.95% |
| 2003 Q3 | -5.9 Million USD | -42.76% |
| 2003 Q4 | -4.62 Million USD | 21.71% |
| 2003 Q2 | -4.13 Million USD | -61.38% |
| 2003 Q1 | -2.56 Million USD | -1.01% |
| 2003 FY | -22.24 Million USD | -83.52% |
| 2002 Q4 | -2.53 Million USD | 3.02% |
| 2002 FY | -12.11 Million USD | -37.32% |
| 2002 Q1 | -1.88 Million USD | 19.29% |
| 2002 Q2 | -2.73 Million USD | -44.52% |
| 2002 Q3 | -2.61 Million USD | 4.21% |
| 2001 Q4 | -2.34 Million USD | -18.72% |
| 2001 FY | -8.82 Million USD | 10.81% |
| 2001 Q3 | -1.97 Million USD | 50.52% |
| 2001 Q2 | -3.98 Million USD | -123.68% |
| 2001 Q1 | -1.78 Million USD | 28.12% |
| 2000 Q1 | -1.17 Million USD | -72.52% |
| 2000 Q3 | -1.72 Million USD | 49.3% |
| 2000 FY | -9.89 Million USD | -72.42% |
| 2000 Q2 | -3.39 Million USD | -189.86% |
| 2000 Q4 | -2.47 Million USD | -43.98% |
| 1999 Q2 | -932.11 Thousand USD | -56.23% |
| 1999 Q1 | -596.61 Thousand USD | 8.36% |
| 1999 Q4 | -679.09 Thousand USD | -44.99% |
| 1999 FY | -5.73 Million USD | -83.96% |
| 1999 Q3 | -468.36 Thousand USD | 49.75% |
| 1998 Q1 | -1.05 Million USD | 6.26% |
| 1998 Q2 | -345.86 Thousand USD | 67.18% |
| 1998 Q4 | -651.04 Thousand USD | 31.41% |
| 1998 Q3 | -949.12 Thousand USD | -174.42% |
| 1998 FY | -3.11 Million USD | 3.32% |
| 1997 Q4 | -1.12 Million USD | -56.18% |
| 1997 Q3 | -719.94 Thousand USD | 0.0% |
| 1997 FY | -3.22 Million USD | 7.35% |
| 1996 FY | -3.48 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | -1254.356% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | -36.947% |
| Helix BioPharma Corp. | -9.26 Million CAD | -452.753% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -129593.792% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | -101.08% |
| Satellos Bioscience Inc. | -15.88 Million CAD | -222.28% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | -84.516% |
| Sernova Corp. | -38.99 Million CAD | -31.308% |